Paper Details

  1. Home
  2. Paper Details

Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.

Author: Bekaii-SaabTanios S, CohnAllen Lee, El-RayesBassel F, FernandoNishan H, GoldbergRichard M, GroganWilliam, HorganAnne M, IvanovaAnastasia, KasbariSamer S, KimRichard D, LeonardGregory, McCaffreyJohn, McDermottRay, MooreDominic T, O'NeilBert H, O'ReillySeamus, OlowokureOlugbenga O, RyanTheresa, SanoffHanna K, SherrillGary Bradley, YacoubGeorge Hosni, ZamboniWilliam

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Regorafenib, a multikinase inhibitor, was evaluated in combination with FOLFIRI (folinic acid, fluorouracil, and irinotecan) as a second-line treatment for metastatic colorectal cancer. The study aims to determine the efficacy of this combination therapy.
Paper Details　
Original Abstract of the Article :
Regorafenib, a multikinase inhibitor that inhibits angiogenesis, growth, and proliferation, prolongs survival as monotherapy in patients with refractory colorectal cancer. This international, double-blind, placebo-controlled, multicenter trial assessed the efficacy of regorafenib with folinic acid, ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/cncr.31552

データ提供：米国国立医学図書館（NLM）

Regorafenib and FOLFIRI: A New Alliance in Colorectal Cancer Treatment

This study explores the potential benefits of combining regorafenib, a multikinase inhibitor, with FOLFIRI, a chemotherapy regimen, as a second-line treatment for metastatic colorectal cancer. The authors conducted a randomized, double-blind phase 2 trial to evaluate the efficacy of this combination therapy in patients with refractory colorectal cancer. Their findings suggest that this combination might be a promising therapeutic approach for this challenging disease, potentially offering improved outcomes compared to standard chemotherapy alone.

Battling Colorectal Cancer: A Desert of Challenges

This research, like a caravan navigating a treacherous desert landscape, delves into the complexities of colorectal cancer treatment. It's a reminder that ongoing research is constantly seeking new and effective approaches to manage this challenging disease. This study highlights the potential of combining different therapies, like a team of camels working together to overcome obstacles, to achieve better outcomes for patients.

A Reminder to Seek Professional Guidance

This research, like a desert oasis offering relief from the harsh elements, serves as a reminder that colorectal cancer treatment is often complex and requires a multidisciplinary approach. It's crucial to consult with a healthcare professional to develop a personalized treatment plan that meets your individual needs and maximize your chances of achieving a positive outcome.

Dr. Camel's Conclusion

This study, like a caravan discovering a hidden oasis in the vast desert of colorectal cancer research, suggests that combining regorafenib with FOLFIRI might be a promising therapeutic approach for this challenging disease. It's a reminder that ongoing research is leading to new and innovative treatment strategies, offering hope for patients battling this disease.
Date :
  1. Date Completed 2019-09-10
  2. Date Revised 2019-09-10
Further Info :

Pubmed ID

29905927

DOI: Digital Object Identifier

10.1002/cncr.31552

Related Literature

Article Analysis
・Side Effects of regorafenib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.